PL1643983T3 - Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy - Google Patents

Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Info

Publication number: PL1643983T3
Authority: PL; Poland
Prior art keywords: sphingosine; methods; vascular endothelial; vascular permeability; apoptosis
Prior art date: 2003-06-24

Application number

PL04776717T

Other languages

English (en)

Inventor

Timothy Hla

Teresa Sanchez

Ji-Hye Paik

Kevin P Claffey

Original Assignee

Univ Connecticut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-24

Filing date

2004-06-18

Publication date

2010-10-29

2004-06-18 Application filed by Univ Connecticut filed Critical Univ Connecticut

2010-10-29 Publication of PL1643983T3 publication Critical patent/PL1643983T3/pl

Links

230000008728 vascular permeability Effects 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
230000006907 apoptotic process Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 4
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 4
239000000018 receptor agonist Substances 0.000 abstract 3
229940044601 receptor agonist Drugs 0.000 abstract 3
210000004204 blood vessel Anatomy 0.000 abstract 2
230000004528 endothelial cell apoptotic process Effects 0.000 abstract 2
230000003511 endothelial effect Effects 0.000 abstract 2
230000002792 vascular Effects 0.000 abstract 2
210000003556 vascular endothelial cell Anatomy 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
102100027662 Sphingosine kinase 2 Human genes 0.000 abstract 1
101710156532 Sphingosine kinase 2 Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
229960000556 fingolimod Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Obesity (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL04776717T 2003-06-24 2004-06-18 Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy PL1643983T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48223403P	2003-06-24	2003-06-24
PCT/US2004/019420 WO2005002559A2 (en)	2003-06-24	2004-06-18	Methods of inhibiting vascular permeability and apoptosis
EP04776717A EP1643983B1 (en)	2003-06-24	2004-06-18	Methods of inhibiting vascular permeability and apoptosis

Publications (1)

Publication Number	Publication Date
PL1643983T3 true PL1643983T3 (pl)	2010-10-29

Family

ID=33563841

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04776717T PL1643983T3 (pl)	2003-06-24	2004-06-18	Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Country Status (14)

Country	Link
US (3)	US7838562B2 (pl)
EP (1)	EP1643983B1 (pl)
JP (2)	JP2007523858A (pl)
CN (2)	CN101518524A (pl)
AT (1)	ATE466572T1 (pl)
AU (1)	AU2004253473B2 (pl)
BR (1)	BRPI0411831A (pl)
CA (3)	CA2778309C (pl)
DE (1)	DE602004027045D1 (pl)
ES (1)	ES2342396T3 (pl)
MX (1)	MXPA05014216A (pl)
PL (1)	PL1643983T3 (pl)
PT (1)	PT1643983E (pl)
WO (1)	WO2005002559A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003094965A2 (en)	2002-05-08	2003-11-20	Neuronova Ab	Modulation of neural stem cells with s1p or lpa receptor agonists
GB0329498D0 (en) *	2003-12-19	2004-01-28	Novartis Ag	Organic compounds
EP1845971A4 (en) *	2005-01-21	2009-12-30	Medvet Science Pty Ltd	METHOD OF TREATING CELLULAR DAMAGE
KR100773765B1 (ko)	2005-11-24	2007-11-12	재단법인서울대학교산학협력재단	개선된 스핑고신 유사체의 제조 방법
EP1905434A1 (en) *	2006-09-26	2008-04-02	Novartis AG	Organic compounds comprising an S1P receptor agonist and their therapeutic use
PT3103448T (pt) *	2006-09-26	2019-07-12	Novartis Ag	Composições farmacêuticas que compreendem um modulador de s1p
HUE032743T2 (en)	2006-11-22	2017-10-30	Clinical Res Ass Llc	A method for treating Down syndrome, fragilis X syndrome and autism
TW200927142A (en)	2007-10-12	2009-07-01	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
CN102464590B (zh) *	2010-11-18	2013-10-23	中国科学院上海药物研究所	一类免疫调节剂及其制备方法和用途
ES2388273B1 (es) *	2011-03-16	2013-10-01	Consejo Superior De Investigaciones Científicas (Csic)	Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
US9663511B2 (en)	2012-03-26	2017-05-30	Arroyo BioSciences, LLC	Sphingosine 1-phosphate receptor antagonists
WO2013181488A2 (en) *	2012-06-01	2013-12-05	The Ohio State University Research Foundation	Inhibition of leukemic stem cells by pp2a activating agents
WO2014043334A1 (en) *	2012-09-12	2014-03-20	Oklahoma Medical Research Foundation	Modulation of podoplanin mediated platelet activation
EP2990055B1 (en)	2013-04-26	2019-06-05	Kyoto University	Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
JP6190538B2 (ja) *	2014-09-01	2017-08-30	パスロジ株式会社	ユーザ認証方法及びこれを実現するためのシステム
WO2016115092A1 (en) *	2015-01-12	2016-07-21	La Jolla Institute For Allergy And Immunology	Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
CN105395530A (zh) *	2015-11-27	2016-03-16	天津医科大学总医院	芬戈莫德的新用途
CN105640928A (zh) *	2016-02-26	2016-06-08	南京医科大学	Fty720在制备预防与治疗缺血性脑卒药物中的应用
CN108939074B (zh) *	2017-05-22	2022-06-10	北京蔚蓝之源医药科技有限公司	治疗再生障碍性贫血的方法和药物组合物
SG11202006255UA (en) *	2018-02-02	2020-07-29	Univ Kyoto	Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
EP3677259A1 (en) *	2019-01-07	2020-07-08	Mosaiques Diagnostics And Therapeutics AG	Use of arachidonyl trifluoromethyl ketone
WO2022040371A1 (en) *	2020-08-19	2022-02-24	Biogen Ma Inc.	Methods for treating hypercholesterolemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2167805A1 (en) *	1993-07-23	1995-02-02	L. David Tomei	Methods of treating apoptosis and associated conditions
US5948820A (en) *	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
US6043224A (en) *	1996-09-05	2000-03-28	The Massachusetts Institute Of Technology	Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JPH11246434A (ja) *	1998-02-25	1999-09-14	Sumitomo Pharmaceut Co Ltd	ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
EP1070080A4 (en) *	1998-03-09	2004-12-29	Smithkline Beecham Corp	HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
US6964967B2 (en) *	2000-12-11	2005-11-15	Amgen, Inc.	Substituted pyrido[2,3-d]pyrimidines and methods for their use
US6471980B2 (en) *	2000-12-22	2002-10-29	Avantec Vascular Corporation	Intravascular delivery of mycophenolic acid
US20050003455A1 (en) *	2001-08-08	2005-01-06	Yasunobu Okada	Remedies for heart diseases
US20050070506A1 (en) *	2002-01-18	2005-03-31	Doherty George A.	Selective s1p1/edg1 receptor agonists
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds

2004
- 2004-06-18 US US10/562,305 patent/US7838562B2/en not_active Expired - Fee Related
- 2004-06-18 PT PT04776717T patent/PT1643983E/pt unknown
- 2004-06-18 DE DE602004027045T patent/DE602004027045D1/de not_active Expired - Lifetime
- 2004-06-18 WO PCT/US2004/019420 patent/WO2005002559A2/en not_active Ceased
- 2004-06-18 ES ES04776717T patent/ES2342396T3/es not_active Expired - Lifetime
- 2004-06-18 MX MXPA05014216A patent/MXPA05014216A/es active IP Right Grant
- 2004-06-18 CN CN200810212366A patent/CN101518524A/zh active Pending
- 2004-06-18 CA CA2778309A patent/CA2778309C/en not_active Expired - Fee Related
- 2004-06-18 CN CNB2004800175481A patent/CN100431534C/zh not_active Expired - Fee Related
- 2004-06-18 EP EP04776717A patent/EP1643983B1/en not_active Expired - Lifetime
- 2004-06-18 AT AT04776717T patent/ATE466572T1/de active
- 2004-06-18 PL PL04776717T patent/PL1643983T3/pl unknown
- 2004-06-18 JP JP2006517361A patent/JP2007523858A/ja not_active Withdrawn
- 2004-06-18 CA CA2778126A patent/CA2778126A1/en not_active Abandoned
- 2004-06-18 AU AU2004253473A patent/AU2004253473B2/en not_active Ceased
- 2004-06-18 BR BRPI0411831-6A patent/BRPI0411831A/pt not_active IP Right Cessation
- 2004-06-18 CA CA2529318A patent/CA2529318C/en not_active Expired - Fee Related
2010
- 2010-09-30 US US12/894,783 patent/US9101575B2/en not_active Expired - Fee Related
2014
- 2014-01-07 JP JP2014001034A patent/JP2014088421A/ja active Pending
2015
- 2015-06-18 US US14/743,352 patent/US20150283154A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2014088421A (ja)	2014-05-15
US9101575B2 (en)	2015-08-11
US20080039530A1 (en)	2008-02-14
DE602004027045D1 (de)	2010-06-17
JP2007523858A (ja)	2007-08-23
CA2778309A1 (en)	2005-01-13
CA2778309C (en)	2014-12-02
US7838562B2 (en)	2010-11-23
WO2005002559A2 (en)	2005-01-13
AU2004253473B2 (en)	2010-03-04
BRPI0411831A (pt)	2006-08-08
CN100431534C (zh)	2008-11-12
ATE466572T1 (de)	2010-05-15
MXPA05014216A (es)	2006-03-13
AU2004253473A1 (en)	2005-01-13
WO2005002559A3 (en)	2005-04-14
ES2342396T3 (es)	2010-07-06
CN101518524A (zh)	2009-09-02
PT1643983E (pt)	2010-06-18
CA2778126A1 (en)	2005-01-13
US20150283154A1 (en)	2015-10-08
US20110015159A1 (en)	2011-01-20
CA2529318A1 (en)	2005-01-13
EP1643983B1 (en)	2010-05-05
EP1643983A2 (en)	2006-04-12
CA2529318C (en)	2013-09-17
CN1826104A (zh)	2006-08-30

Publication	Publication Date	Title
PL1643983T3 (pl)	2010-10-29	Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
UA98629C2 (ru)	2012-06-11	Соединения и способ модуляции киназ
WO2007136790A3 (en)	2008-11-27	Intracellular kinase inhibitors
MX2009008253A (es)	2009-10-12	Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW200634006A (en)	2006-10-01	Tetrahydroquinoline analogues as muscarinic agonists
MX2007012237A (es)	2007-12-07	Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
WO2008063842A3 (en)	2009-02-19	Methods of treating neuropathic pain with agonists of ppar-gamma
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
MXPA05012678A (es)	2006-02-22	Forma cristalina del agonista del receptor adrenergico beta2.
TW200626068A (en)	2006-08-01	Active compounds for seed treatment
WO2008028141A3 (en)	2008-04-10	Raf inhibitor compounds and methods of use thereof
WO2008060907A3 (en)	2009-06-11	Pyrrolo-pyridine kinase inhibitors
WO2005086860A3 (en)	2009-04-02	Methods for generating insulin-producing cells
MX2009007023A (es)	2009-09-09	Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2009120919A3 (en)	2010-11-04	Fenofibrate dosage forms
WO2007098474A8 (en)	2008-11-06	Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
WO2007092190A3 (en)	2007-11-29	Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
TNSN08140A1 (pl)	2009-07-14
NO20092138L (no)	2009-07-13	Forbindelser og sammensetninger som proteinkinase inhibitorer
EA201100255A1 (ru)	2011-08-30	5-алкинилпиримидины
WO2006007378A3 (en)	2006-05-04	Pyrrolotriazine kinase inhibitors
EA201100254A1 (ru)	2011-08-30	Новые соединения
WO2009140972A3 (en)	2010-06-17	Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
TW200833688A (en)	2008-08-16	Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
NZ596104A (en)	2014-01-31	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof